Search Results

JDRF and Sanofi Canada are announcing a partnership aimed at amplifying awareness around type 1 diabetes, a chronic autoimmune condition, and the role screening could play in the early detection of this disease.

vTv Therapeutics Inc. announced that it has closed a private placement to healthcare-focused institutional investors, including a life sciences-focused institutional investor, Samsara BioCapital, LLC and the JDRF T1D Fund, of 464,377 shares of common stock at a price of $11.81 per share, which is the 45 day VWAP ended on January 29, 2024, and pre-funded warrants for 3,853,997 shares of common stock in lieu of vTv common stock in a private placement financing.

NexImmune, Inc. announces the extension of the research partnership between NexImmune, Yale and JDRF to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells.

Diamyd Medical is hosting a webcast presentation on October 20th at 2:00 pm CET / 8:00 am EDT with Ulf Hannelius, CEO of Diamyd Medical, Josh Vieth, Director of Research at JDRF, as well as Mark Atkinson, Director for the University of Florida Diabetes Institute and member of the Board of Directors of Diamyd Medical.

Zucara Therapeutics Inc. announced additional funding from JDRF, the leading global Type 1 diabetes research and advocacy organization.

JDRF, the leading global type 1 diabetes research and advocacy organization, urged members of the Senate Appropriations Committee to renew the Special Diabetes Program and support policies to ensure insulin is available at an affordable and predictable price.

In recognition of Healthy Vision Month, JDRF, the leading global type 1 diabetes research and advocacy organization, encourages everyone living with diabetes to be proactive about their eye health.

JDRF joined thousands within the diabetes community at the American Diabetes Association’s 83rd Scientific Sessions, where hundreds of experts presented significant advancements in diabetes research that may prove to be pivotal in improving lives and finding cures for T1D.

EVOQ Therapeutics, Inc. today announced a collaboration with JDRF for the development of a new drug platform for antigen-specific immune-tolerizing therapy against Type 1 diabetes (T1D).

The results of the PROTECT clinical trial shared today by Sanofi and presented at the International Society for Pediatric and Adolescent Diabetes (ISPAD) annual conference demonstrate that TZIELD, the first disease-modifying therapy available to delay clinical T1D in people at risk of developing the disease, can also be effective in newly diagnosed children and adolescents ages 8-17.